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Abstract: The purpose of this review was to look at the evidence available for the use of atosiban as a tocolytic in cases of threatened 
preterm labour. A Royal College of Obstetricians and Gynaecologists Green Top Guideline concluded that there was no clear evidence 
to show a benefit to tocolysis in reducing perinatal and neonatal morbidity and mortality.  Using a systematic literature search, we 
summarise the evidence available on the use of atosiban for the prevention of preterm birth and compare it with other commonly used 
tocolytic agents in terms of efficacy, patient preference and drug safety.   We conclude that although atosiban appears to be the tocolytic 
of choice, a clear benefit of using tocolysis in all cases of threatened preterm labour remains to be justified and clinical management 
should be tailored according to individual needs.
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Introduction
Preterm delivery is defined as birth before 37 com-
pleted weeks of pregnancy. It is associated with signif-
icant morbidity and mortality to the  resulting babies, 
and emotional and financial costs to the  parents. 
Outcome is related to the gestation at which the deliv-
ery occurs with babies being born at earlier gesta tions 
having the more severe complications. Mortality 
rates vary from around 20% at 26 weeks1 to 2.3% at 
34–36 + 6 weeks gestation,2 with increasing rates of 
respiratory distress syndrome, feeding difficulties and 
hypothermia and long term developmental problems 
seen in the more preterm babies.
The rate in the UK is rising. In 2005, 6% of 
 singleton pregnancies and 53% of multiple pregnan-
cies were born prematurely in England and Wales.3 
Worldwide, prematurity affects 9.6% of all births4 
and accounts for approximately 1 million neonatal 
deaths annually, with low income countries reporting 
5 times higher rates of preterm birth than high income 
countries.5
In most cases the exact cause of preterm labour 
or threatened preterm labour is unknown.5 The 
 reasons are thought to be multifactorial, and vary 
with  gestational age, ethnicity, geography and social 
factors.6 There are situations where early delivery is 
indicated for the safety of the mother or baby such 
as pre-eclampsia, placental abruption, haemorrhage 
or intrauterine infection. In other cases, where the 
cause is less clear, much discussion and research has 
taken place over past years to determine the benefit 
of  prolonging the pregnancy in spontaneous preterm 
labour using tocolytic medication.
The Royal College of Obstetricians and Gynaecol-
ogists produced a guideline in 20027 looking at the 
role of tocolytic drugs. They concluded that there 
was no clear evidence to show that tocolytic drugs 
improved perinatal or infant mortality or serious 
 neonatal  morbidity. The important effect was in 
 reducing the numbers delivering within 7 days. This 
means  tocolysis can be considered if gaining  benefit 
from those days would allow administration of 
 steroids of transfer to a unit with appropriate neonatal 
care, which are proven to improve outcome.
Different types of tocolytics have been  investigated. 
These include beta-agonists, calcium channel block-
ers, magnesium sulphate, prostaglandin  synthetase 
inhibitors.7 Atosiban is an oxytocin  receptor  antagonist 
and in this review, we will look at the  evidence 
 surrounding atosiban and its role in preventing pre-
term labour.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Atosiban is a synthetic peptide which acts as a 
 competitive antagonist of oxytocin at human 
 uterine oxytocin receptors. Oxytocin causes  uterine 
contractions through a direct effect on  membrane 
bound receptors in the uterus by increasing 
the  concentration of intracellular calcium in the 
 myometrial cells. It can also lead to cervical  ripening 
by stimulating the release of prostaglandins in the 
decidual and fetal membranes. Atosiban has been 
shown to result in inhibition of uterine contractility 
and a decrease in prostaglandin release. This occurs 
rapidly, with a reduction in contractions being seen 
within ten minutes.8
Atosiban is given as an initial bolus dose of 
6.75 mg followed by an infusion of 7.5 mg/ml given 
at a rate of 24 ml/hour for 3 hours then reduced to 
8 ml/hour for up to 45 hours. Total atosiban dose 
should not exceed 330 mg. Steady state plasma levels 
are reached within an hour of starting the infusion.8 
Atosiban clearance, volume of distribution and half 
life are independent of the dose. Once the infusion is 
stopped, plasma concentrations decline rapidly with 
an initial (t∆) and terminal (tE) half life of 0.21 ± 0.01 
and 1.7 ± 0.3 hours respectively.8
Two metabolites have been identified, M1 and 
M3, in the plasma and urine of women. M1, the 
main metabolite, is as potent as atosiban in  inhibiting 
contractions in vitro.8 The ratio of M1 to atosiban is 
1.4 and 2.8 at the second hour and at the end of the 
infusion respectively.8 Atosiban is detected only in 
small quantities in the urine with the concentration 
of M1 detected being 50× higher than atosiban itself.8 
M1 is also excreted in breast milk.8
Atosiban does cross the placenta. A dose of 
300 mcg/min administered at term to a healthy 
 pregnant woman gives a fetal/maternal atosiban 
 concentration ration of 0.12.8
clinical studies
There have been clinical trials to evaluate the effi-
cacy and safety of atosiban. These have looked 
at atosiban versus placebo, and other tocolytics, 
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most  commonly beta-mimetics and calcium  channel 
blockers.  Outcomes of interest vary among studies 
but the primary aim is generally delay to delivery 
with  secondary outcomes relating to neonatal and 
 maternal morbidity.
Atosiban versus placebo
A recent Cochrane review9 studied the role of 
 atosiban in preventing preterm labour. It identified 
two  trials comparing atosiban with placebo,  involving 
651 women. No benefit was found in reducing the 
preterm delivery rate in either study.10,11
Romero et al10 carried out a multicentre double 
blind placebo controlled trial involving 531 patients 
across 37 centres. The primary outcome was time 
from treatment to delivery or treatment failure, 
which  constituted progression of labour requiring an 
 alternative tocolytic. No significant difference was 
seen in primary outcome (25.6 vs. 21 days; P = 0.6) 
between atosiban and placebo. The  secondary  outcome 
was proportion undelivered at 24 hours, 48 hours and 
7 days. In all 3 categories, there was a significant 
increase in patients undelivered in the atosiban group. 
This is important as this group did not include those 
that received additional rescue  tocolysis unlike 42% 
of the  overall participants in the atosiban group and 
51% of the placebo recipients. Rescue  tocolysis of 
an alternative unnamed  tocolytic was used if labour 
progressed after discontinuation of the study drug 
or during the infusion, and the type of medication 
was the researcher’s discretion. When looking at the 
 gestational age at which  tocolysis was used, there was 
a benefit shown for atosiban use in pregnancies over 
28 weeks, with more women remaining undelivered at 
both 48 hours and 7 days. At earlier  gestations, there 
was no  benefit, but this study included cases from 
20 weeks  putting its generalisability in doubt. The 
reasons for the increased effectiveness at advanced 
gestations are unclear. While there may be questions 
raised from this study about the benefits of atosiban use 
below 28 weeks, it is accepted that in  clinical practice 
the majority of women presenting with threatened pre-
term labour in whom tocolysis would be considered 
are in later  gestations. One concerning finding from 
this study was the increase in the rate of fetal deaths 
in the treatment group (4.5% vs. 1.7%). This has been 
explained by the imbalance in early  gestations in the 
treatment group despite randomisation (24% vs. 13%). 
Seven out of the 10 patients in the atosiban group who 
had a fetal death were under 24 weeks at enrolment 
and may not have received tocolysis under normal 
clinical  conditions. This study showed strength in its 
computer based randomisation and intention to treat 
analysis.
Goodwin et al,11 in contrast, used atosiban or 
placebo for a maximum time of 2 hours. This is a 
randomised double-blind placebo-controlled trial 
involving 120 women between 20 and 36 weeks 
 gestation. Their primary outcome was uterine activity, 
with a statistically significant decrease in contraction 
frequency demonstrated by external tocodynamome-
try with atosiban (55.3% vs. 26.7%; P , 0.001). Like 
Romero et al, rescue tocolysis, with magnesium sul-
phate, was used and required in 18.3% of the atosiban 
group compared to 30% in the placebo group. Both 
studies utilised high levels of rescue treatment which 
affect the ability to make clear conclusions regarding 
efficacy.
Other studies not included in the Cochrane review 
have shown a benefit to atosiban in reducing the 
 delivery rate.12 Husslein et al included 226 women 
over 105 centres to immediate or standard treatment 
with atosiban. Two criteria was used for inclusion, and 
patients were assigned to the immediate treatment arm 
if they had one of regular uterine contractions lasting 
at least 30 seconds at a rate of 4 per 30 minutes or 
 cervical dilatation of 1–3 cm in multiparous women 
or 0–3 cm in nulliparous women and 50% effacement; 
those in the standard treatment arm met both  criteria. 
This was a prospective, open labelled randomised 
trial. There was a significant increase in women unde-
livered at 48 hours compared to those who received 
no treatment (77.6% vs. 56.6%; P , 0.001). When 
used outwith a comparative study, atosiban showed 
cessation of uterine activity in 70.5% and 80% of 
patients when used over 12 hours and up to 45 hours 
respectively.13,14
Atosiban versus beta-mimetics
Three trials15–17 included in the Cochrane review 
 compared atosiban with betamimetics and were 
regarded as high quality. In total, 1044 women 
were involved and the authors concluded that there 
were no significant differences between reduction 
in delivery at 48 hours, neonatal respiratory distress 
or admission to neonatal intensive care. However, 
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the rate of maternal adverse drug reaction was higher 
in the beta-mimetic group resulting in more women 
 ending treatment early. The lower discontinuation rate 
and comparable efficacy led researchers in  Germany 
to conclude that atosiban is more cost effective than 
beta-mimetics.18
The European Atosiban Study Group15 was a 
multicentre, double-blind, double-placebo ran-
domised controlled trial involving 249 women 
between 23 and 33 weeks gestation in  suspected 
preterm labour where 31 treatment centres across 
4 countries were involved. Atosiban was  compared 
to terbutaline, with no  significant  difference detected 
in numbers remaining undelivered at 48 hours 
(86.1% vs. 85.3%; P = 0.78) and 7 days (76.5% vs. 
67.4%; P = 0.07). There was no  significant  difference 
in gestational age at  delivery between the two groups; 
which included  singleton and  multiple pregnancies. 
Fetal adverse effects showed a wide  difference for 
tachycardia .170 bpm between the two groups but 
this did not result in  cessation of  treatment in either 
group.  Outcomes were  comparable for neonatal/infant 
adverse effects. Maternal adverse effects (see Table 1) 
resulted in a higher  percentage of women discontinuing 
the  treatment in the  terbutaline group compared to 
 atosiban (13.2% vs. 1.7%). This study represents a 
wide spectrum of subjects with clearly defined inclu-
sion  criteria, making its applicability clear across 
similar populations.
The French/Australian Atosiban  Investigators 
Group16 carried out a multicentre, double-blind, 
 double-placebo, randomised controlled trial 
comparing  atosiban with intravenous salbutamol. 
This study was conducted across 331 treatment 
 centres in France and 5 in Australia, and utilised 
 computer generated  randomisation to reduce risk 
of bias. Women between 23 and 33 weeks  gestation 
were included, (n = 241), representing an  optimal 
gestation range, but  multiple pregnancies were 
 over-represented above 28 weeks in the salbutamol 
group. No significant  difference in numbers undeliv-
ered at 48 hours (93.3% vs. 95.0%; P = 0.67) or 7 days 
(89.9% vs. 90.1%; P = 0.93) was found between 
the atosiban and salbutamol groups respectively, 
 however, the use of an alternative  tocolytic due to 
initial treatment  failure was  significantly higher in the 
salbutamol group at 7 days.  Gestational age at delivery 
was similar for both groups. Like the  European 
 Atosiban Study Group, there was an increase in fetal 
 tachycardia in the beta-mimetic treatment group 
(4.2% vs. 20.5%), with  comparable neonatal/infant 
outcomes.  Similarly, treatment  discontinuation was 
higher in the  salbutamol group (0.8% vs. 10.7%). 
The study findings should be relatively generalisable 
to developed world settings, given the heterogeneity 
of the study centres involved, and the pragmatic 
approach to inclusion of multiple pregnancies.
A third multicentre, double-blind, randomised 
 controlled trial compared atosiban to ritodrine.17 This 
trial included 252 women at 23 to 33 weeks gesta-
tion and the results showed no significant difference 
in those remaining undelivered at 48 hours (84.9 vs. 
86.8%; P = 0.99) and at 7 days (73% vs. 76%; P = 0.85) 
in the atosiban or ritodrine group respectively. As with 
the previous two studies, gestational age at delivery 
was comparable (35.1 vs. 35.2; P = 0.86); there was 
a higher rate of fetal tachycardia (0% vs. 17.4%) but 
similar neonatal outcomes. Maternal discontinuation 
of treatment was also in line with other studies and 
showed a higher rate of discontinuation in the beta-
mimetic arm (0.8% vs. 29.8%).
Atosiban versus nifedipine
Atosiban has been compared to nifedipine in two 
 randomised controlled trials involving 80 and 
63 women respectively.19,20 A meta-analysis of indi-
rect randomised controlled trials has also been done 
comparing the two drugs.20
Kashanian et al19 carried out a randomised trial 
involving 80 women at 26 to 34 weeks  gestation. They 
did not find a significant difference in the effectiveness 
of tocolysis between atosiban and  nifedipine at 
48 hours (82.5% vs. 75%) or at 7 days (75% vs. 65%) 
but results suggested a trend towards the increased 
effectiveness of atosiban. As this study was looking at 
several outcomes, it is likely to be under-powered with 
just 80 subjects which included multiple pregnancies.
Al Omari et al20 included 63 women between 24 and 
35 weeks gestation in a randomised controlled trial 
using intravenous atosiban and oral nifedipine. No 
significant difference in rates of delivery at 48 hours 
(77.4% vs. 81.3%; P = 0.474) and 7 days (74.2% 
vs. 70.96%; P = 0.421) were found in the atosiban 
group compared to nifedipine group respectively. 
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However, nifedipine was significantly more effective 
at  reducing delivery rate at 48 hours in those below 
28 weeks  gestation (20% vs. 100%; P = 0.0.404).
Similar results were obtained in the meta- analysis.21 
No significant difference between  delivery rates at 
48 hours were found between  nifedipine and atosiban, 
however, there was a trend to  reduction in delivery 
rate at 48 hrs in the nifedipine arm. This  contradicts 
the findings by Kashanian et al. A  significant 
decrease in neonatal respiratory distress was seen in 
the  nifedipine arm of the meta-analysis but this was 
not confirmed by Al-Omari et al who did not find any 
difference in neonatal outcomes.  Neonatal outcomes 
were not assessed by Kashanian et al. Maternal side 
effects were similar in both  comparative studies 
and not commented on by Coomarasamy et al. 
Kashanian et al showed an significantly increased 
rate of  maternal side effects in the nifedipine group 
(40% vs. 17%; P = 0.027), in particular vertigo and 
hypotension. This was also found by Al Omari et al 
who  demonstrated a significant increase in side 
effects, namely headache, palpitations, flushing and 
hypotension, with  nifedipine. During administration 
of the atosiban bolus dose, there was a significant 
increase in nausea in these patients (74.4% vs. 9.9%; 
P = 0.00001).
Concerns exist as to the reliability of an indirect 
comparison for making conclusions that will aid 
 clinical practice. The direct trials mentioned did not 
use a blinding format and so taken together, the  quality 
of the available evidence could be improved to draw 
comparisons between atosiban and nifedipine.
Other
Research has also looked into the timing of adminis-
tration of atosiban. A Cochrane review suggested no 
benefit from long-term atosiban maintenance therapy 
following an episode of threatened preterm labour.22 
This review included only one trial14  involving 
513 women. This was a multicentre, double-blind, 
 placebo-controlled trial. Patients were included after 
initially responding to atosiban therapy.  Thereafter, 
they were assigned to atosiban maintenance or 
 placebo, both administered subcutaneously, until the 
end of week 36. The primary outcome was time to 
first recurrence of labour and there was a  significantly 
increased period of gestation in the atosiban group 
(36.2 days vs. 28.2 days; P = 0.03). There was  however 
no reduction in preterm birth or benefit to neonatal 
outcome and maintenance therapy in both groups 
was associated with maternal inconvenience. The 
 atosiban group showed an increased rate of injection 
site  reactions compared to the placebo group.
Difficulties have been identified  throughout 
the studies which should be considered when 
 interpreting the results. Since atosiban works by 
 acting on  oxytocin receptors in the myometrium, its 
effectiveness may be gestation dependent, with more 
 receptors available with increasing gestations per-
haps explaining why atosiban may be more effective 
at later  gestations. This has been shown in published 
studies10 but the exact reason for the findings has not 
been determined.
There is also some difficulty in clinically diagnos-
ing threatened preterm labour, so selecting appropri-
ate patients for treatment is challenging. This was 
addressed by a randomised trial comparing immediate 
atosiban use with standard administration when either 
regular uterine contractions or cervical dilatation 
were confirmed.12 Only 50% of women in the latter 
group received tocolytic medication, demonstrating 
the high probability that many women presenting 
will not go on to show signs of labour. Those given 
 atosiban immediately had a lower delivery rate within 
48 hrs compared to those who received it after dem-
onstrating signs of labour. There was no significant 
difference in delivery rate after 48 hrs or gestational 
age at delivery.
The lack of good quality clinical studies into 
 tocolysis and preterm labour is highlighted in the 
RCOG Consensus Statement on Preterm Birth.23 
They recommend future research should be  carried 
out with randomised placebo controlled trials, 
focussing on tocolytic benefits in general and a direct 
 comparison of atosiban and nifedipine.  However, 
with the  current advice available stating that  tocolysis 
should be  considered to gain time for proven  therapies 
that will improve outcome (steroids and transfer for 
neonatal facilities) further placebo  controlled  trials 
may be controversial to carry out. We must also be 
careful to evaluate results comparing efficacy of 
 different agents in view of the common practice of 
rescue tocolysis. This practice has the potential to 
skew results.
Fullerton et al
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safety
There is no report of serious adverse effects of 
 atosiban use. It is associated with minor side effects 
in  particular nausea, hyperglycaemia, headache, 
 dizziness and  palpitations. Since data do not strongly 
recommend one tocolytic over another on the basis of 
delivery delay or outcome, maternal tolerance is often 
considered as a significant consideration. Table 1 
summarises the rate of adverse effects.  Atosiban has 
a lower rate of adverse effects than the alternative 
tocolytic medication and is therefore better  tolerated 
by patients. There is no evidence of a relationship 
between atosiban and fetal distress and it may be 
useful in the management of acute fetal hypoxia 
 suggested by a cardiotocograph.23
patient preference
Administration of atosiban is associated with minor 
side effects but these are less than other tocolytics. 
In a comparison of atosiban with beta-agonists, there 
was less cessation of treatment due to side effects in 
the atosiban group.9,18 The overall rate of atosiban 
cessation due to maternal side effects is thought to 
be 0%–1%.26
For those in preterm or threatened preterm labour, 
the reason for tocolysis is for benefit to be gained 
from administration of steroids or transfer to a more 
suitable neonatal unit.7,27 When counselling women, 
the evidence is strong for the benefit of steroids. 
The transfer for experienced neonatal care is more 
upsetting to parents to deal with but the benefits to 
neonatal outcome are proven. In these situations, 
most parents would be expected to accept minor side 
effects and inconvenience for the overall improved 
neonatal morbidity.
In the study comparing immediate administration 
of atosiban with treatment after specific criteria of 
contraction duration/frequency or cervical changes 
were met, patient satisfaction was also studied.12 
This identified a significant increase in satisfaction in 
those that received atosiban early despite no differ-
ence in admission time, gestational age at delivery, 
mode of delivery or numbers receiving steroids. This 
is probably due to the high levels of anxiety that exist 
in these situations and patients feel more reassured if 
they perceive preventative action to be taken even if 
the outcome is the same.
place in Therapy
Atosiban is licenced for use as a tocolytic. Its  efficacy 
is similar to other tocolytic drugs but with a better 
side effect profile. Administration can provide time 
to allow transfer for suitable neonatal facilities or 
 prescription of steroids. The clinical difficulty is when 
to give atosiban and to whom.
Current prescription advice8 is to give atosiban 
in those with regular uterine contractions of at least 
30 seconds duration at a rate of $4 per 30 minutes 
or cervical dilatation or 0–3 cm and effacement 
of $50%. The gestation should be between 24 and 
33 completed weeks and with normal fetal heart. The 
patient should be $18 years.
Controversies exist as to the benefit of administer-
ing atosiban outwith these criteria. It is shown that late 
preterm births result in increased neonatal morbidity, 
although the rate of neonatal mortality is extremely 
low.2,28 The rates of respiratory distress, sepsis work 
ups and phototherapy are all increased leading to 
 longer hospital stays and increased numbers  requiring 
intensive care admission. Would tocolysis provide 
some benefit in these circumstances? The argument 
against however is that no significant benefit has been 
shown to steroid administration after 34 weeks and 
since that is the main indication for tocolysis, its use 
in late preterm labour is not indicated.
For threatened preterm labour before 24 weeks the 
evidence for atosiban use is limited. A small study 
of 40 women in threatened preterm labour between 
Table 1. Side effect profile.20,24
side effect Atosiban Betamimetics placebo Atosiban nifedipine
Nausea 13.9 15.9 5.6 74.4 9.9
Headache 9.3 18.5 7.7 9.7 46.9
Dizziness 2.6 1.9 0.8 – –
Maternal tachycardia 2.5 75.5 1.2 3.2 18.8
Fetal tachycardia 0.9 26.3 – – –
Atosiban for preterm labour
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18 and 24 weeks were given atosiban or placebo.29 
This showed a slight prolongation of pregnancy in 
the treatment group (17.1 weeks versus 15.6 weeks) 
and a cessation of contractions within 12 hours. The 
 numbers in this study are small and routine use  cannot 
be implied from this data. The numbers of women 
suitable for tocolysis in the previable group is very 
small as strict criteria need to be adhered to in order 
to prevent complications such as infection.
Little evidence exists for the use of atosiban in 
cases of preterm prelabour rupture of  membranes 
(PPROM). Studies have looked at the use of 
other tocolytics in PPROM and found no benefit 
in prolongation of pregnancy,30–32 with one study 
 showing a 2.5 fold increase in chorioamnionitis 
after long term tocolysis in women with PPROM.33 
No studies were found directly looking at atosiban 
use in patients with PPROM. In selected cases where 
benefit can be gained from prolonging the pregnancy 
without detriment to the fetus or mother, short term 
use of atosiban could be considered. Further clinical 
studies are required to look at this issue.
Two case reports exist showing use of atosiban for 
prophylactic prevention of preterm labour;34,35 both 
following transabdominal cervico-isthmus in women 
with poor obstetric histories. The first used atosiban 
from 24–32 weeks and the second 16–32 weeks. Both 
had successful outcomes. These are unusual cases 
and consideration of such treatment must be on an 
individual basis.
conclusions
Atosiban appears to be the preferred tocolytic for 
use in view of its improved tolerability and equal 
efficacy to the alternative agents. Still the discussion 
continues, however, as to the overall use of tocolysis 
in cases of threatened preterm labour.
Clinical judgement of each individual case 
should be used in deciding whether to commence 
atosiban therapy. If harm is unlikely to occur with 
prolongation of pregnancy, the benefit from  gaining 
time to allow steroid administration or transfer for 
neonatal  facilities should be the outcome used to 
determine use.
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